In recent years, genetic engineering technology has become an indispensable key technology in the field of biopharmaceutical. Genetic engineering technology can significantly improve the production efficiency and efficacy of drugs by manipulating and modifying genes. This paper analyzes the application of genetic engineering technology in the field of biopharmaceutical, introduces its successful cases, and discusses the great value of genetic engineering technology in the field of biopharmaceutical. This paper first summarizes the classification and development of biopharmaceutical field, and then introduces the principle and method of genetic engineering technology in detail. Then the specific application of genetic engineering technology in biopharmaceutical field is analyzed. Finally, the application prospect of genetic engineering technology in biopharmaceutical field is prospected. With the continuous progress of technology and the improvement of regulations, genetic engineering technology will certainly bring revolutionary changes to the field of biopharmaceutical and benefit human health.

Wenjia Dou. Analysis of the value of genetic engineering technology in the field of biopharmaceuticals. International Journal of Frontiers in Medicine (2024), Vol. 6, Issue 5: 41-47. https://doi.org/10.25236/IJFM.2024.060507.

[1] Barolo L, Abbriano R M, Commault A S, et al. Perspectives for glyco-engineering of recombinant biopharmaceuticals from microalgae[J]. Cells, 2020, 9(3): 633.

[2] Han X, Alu A, Liu H, et al. Biomaterial-assisted biotherapy: A brief review of biomaterials used in drug delivery, vaccine development, gene therapy, and stem cell therapy[J]. Bioactive Materials, 2022, 17: 29-48.

[3] Madhavan A, Arun K B, Sindhu R, et al. Customized yeast cell factories for biopharmaceuticals: from cell engineering to process scale up[J]. Microbial Cell Factories, 2021, 20(1): 124.

[4] Jin F J, Hu S, Wang B T, et al. Advances in genetic engineering technology and its application in the industrial fungus Aspergillus oryzae[J]. Frontiers in Microbiology, 2021, 12: 644404.

[5] Roesch A, Zölls S, Stadler D, et al. Particles in biopharmaceutical formulations, part 2: an update on analytical techniques and applications for therapeutic proteins, viruses, vaccines and cells[J]. Journal of pharmaceutical sciences, 2022, 111(4): 933-950.

[6] Suh K, Kyei I, Hage D S. Approaches for the detection and analysis of antidrug antibodies to biopharmaceuticals: A review[J]. Journal of separation science, 2022, 45(12): 2077-2092.

[7] Cring M R, Sheffield V C. Gene therapy and gene correction: targets, progress, and challenges for treating human diseases[J]. Gene therapy, 2022, 29(1): 3-12.

[8] Chakraborty C, Sharma A R, Sharma G, et al. Therapeutic advances of miRNAs: A preclinical and clinical update[J]. Journal of advanced research, 2021, 28: 127-138.

[9] Matić Z, Šantak M. Current view on novel vaccine technologies to combat human infectious diseases [J]. Applied microbiology and biotechnology, 2022, 106: 25-56.

[10] Akram M, Jabeen F, Daniyal M, et al. Genetic engineering of novel products of health significance: Recombinant DNA technology[J]. Functional Foods and Nutraceuticals: Bioactive Components, Formulations and Innovations, 2020: 595-611.

[11] Shanmugaraj B, I. Bulaon C J, Phoolcharoen W. Plant molecular farming: A viable platform for recombinant biopharmaceutical production[J]. Plants, 2020, 9(7): 842.

[12] Kowalczyk T, Merecz-Sadowska A, Picot L, et al. Genetic manipulation and bioreactor culture of plants as a tool for industry and its applications[J]. Molecules, 2022, 27(3): 795.

[13] Gutiérrez S, Lauersen K J. Gene delivery technologies with applications in microalgal genetic engineering [J]. Biology, 2021, 10(4): 265.

[14] Ahmar S, Saeed S, Khan M H U, et al. A revolution toward gene-editing technology and its application to crop improvement[J]. International Journal of Molecular Sciences, 2020, 21(16): 5665.

[15] Jeong B, Jang J, Jin E S. Genome engineering via gene editing technologies in microalgae[J]. Bioresource Technology, 2023, 373: 128701.

[16] Jin F J, Hu S, Wang B T, et al. Advances in genetic engineering technology and its application in the industrial fungus Aspergillus oryzae[J]. Frontiers in Microbiology, 2021, 12: 644404.

[17] Soldi M, Sergi L S, Unali G, et al. Laboratory-scale lentiviral vector production and purification for enhanced ex vivo and in vivo genetic engineering[J]. Molecular Therapy-Methods & Clinical Development, 2020, 19: 411-425.

[18] Das P K, Sahoo A, Veeranki V D. Current status, and the developments of hosts and expression systems for the production of recombinant human cytokines[J]. Biotechnology Advances, 2022, 59: 107969.

[19] Meng Huan, Su Yifan, Wang Sa, Zhang Shuwen, Zheng Yongxiang, Yu Rong, Zhang Chun. Prokaryotic soluble expression, purification, characterization and preliminary activity evaluation of recombinant albumin-binding peptide fused human interleukin-11 [J]. Chinese Journal of Bioengineering, 2023,43(7):44-52.

[20] Ottaviano G, Georgiadis C, Gkazi S A, et al. Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia[J]. Science translational medicine, 2022, 14(668): eabq3010.

[21] Jin F J, Hu S, Wang B T, et al. Advances in genetic engineering technology and its application in the industrial fungus Aspergillus oryzae[J]. Frontiers in Microbiology, 2021, 12: 644404.

[22] Ba F, Ji X, Huang S, et al. Engineering Escherichia coli to utilize erythritol as sole carbon source[J]. Advanced Science, 2023, 10(14): 2207008.

[23] Imai Y, Meyer K J, Iinishi A, et al. A new antibiotic selectively kills Gram-negative pathogens[J]. Nature, 2019, 576(7787): 459-464.

[24] Battineni J K, Boggula N, Sirikonda S, et al. Recombinant DNA Technology in Previous, Present and Future with Examples[J]. Advances in Multidisciplinary Research and Development, 2021: 1.

[25] Mathieu C, Ásbjörnsdóttir B, Bajaj H S, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial[J]. The Lancet, 2023, 401(10392): 1929-1940.

[26] Porcellati F, Lucidi P, Candeloro P, et al. Pharmacokinetics, pharmacodynamics, and modulation of hepatic glucose production with insulin glargine U300 and glargine U100 at steady state with individualized clinical doses in type 1 diabetes[J]. Diabetes Care, 2019, 42(1): 85-92.

[27] Durand J, Dogné J M, Cohet C, et al. Safety Monitoring of COVID‐19 Vaccines: Perspective from the European Medicines Agency[J]. Clinical Pharmacology & Therapeutics, 2023, 113(6): 1223-1234.

[28] Consoli S, Dono F, Evangelista G, et al. Status migrainosus: A potential adverse reaction to Comirnaty (BNT162b2, BioNtech/Pfizer) COVID-19 vaccine—A case report[J]. Neurological Sciences, 2021: 1-4.

[29] Wang X. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine[J]. N Engl J Med, 2021, 384(16): 1577-1578.

[30] Oliver S E. Use of the Janssen (Johnson & Johnson) COVID-19 vaccine: updated interim recommendations from the advisory committee on immunization practices—United States, December 2021[J]. MMWR. Morbidity and Mortality Weekly Report, 2022, 71.

[31] Gui Y, Cao Y, He J, et al. Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SYS6006, as a fourth-dose booster following three doses of inactivated vaccines in healthy adults: an open-labeled Phase 1 trial[J]. Life Metabolism, 2023, 2(3): load019.

[32] Pecetta S, Rappuoli R. mRNA, the beginning of a new influenza vaccine game[J]. Proceedings of the National Academy of Sciences, 2022, 119(50): e2217533119.